-+ 0.00%
-+ 0.00%
-+ 0.00%

*Johnson & Johnson: 3Q Innovative Medicine Operational Sales Growth Driven Primarily by Tremfya, Darzalex, Carvykti, Tecvayli, Rybrevant/Lazcluze, Erleada, Caplyta and Spravato >JNJ

Dow Jones·10/13/2026 10:20:00

Please log in to view news